LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

William Sandborn  ¹     Brian G. Feagan  ²     Stephen B Hanauer  ³     Severine Vermeire  ⁴     Subrata Ghosh  ⁵     Wenzhong Liu  ⁶     AnnKatrin Petersen  ⁶     Lorna Charles  ⁶     Vivian Huang  ⁶     Keith Usiskin  ⁶     Douglas C. Wolf  ⁷     Geert R. D'Haens  ^8    
1 University of California San Diego, La Jolla, United States
² Robarts Research Institute, Ontario, Canada
³ Feinberg School of Medicine, Chicago, United States
⁴ University of Leuven, Leuven, Belgium
⁵ University of Calgary, Alberta, Canada
⁶ Bristol Myers Squibb, Summit, United States
⁷ Center for Crohn’s Disease & Ulcerative Colitis, Atlanta, United States
⁸ Inflammatory Bowel Disease Center, Amsterdam, Netherlands

Topic
IBD, Immunology

Session
IBD: Clinical trials I

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)